Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide/Fludarabine and DLI After Allogeneic Transplant
NCT00167180Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2004
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, fludarabine in chronic myeloid leukemia (CML), lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), sponsored by Masonic Cancer Center. Started Jan 2004; status: terminated.
02
Drugs
cyclophosphamidefludarabine
03
Conditions
chronic myeloid leukemia (CML)lymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00167180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167180.